Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PINNACLE: REGN7544 in Postural Orthostatic Tachycardia Syndrome (POTS)
NCT06593600Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of baloncibart in postural orthostatic tachycardia syndrome (POTS) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Change in Heart Rate from supine to standing at Day 8 and Change from baseline in DeltaHR-avg at Day 29. Started Nov 2024; status: completed.
02
Drugs
baloncibart
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT06593600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593600.